Back to all blog posts
Dear customers, partners, shareholders, and our team,
As we enter a new year filled with possibilities, I want to reflect on the impact we made in 2025. Aiforia is making significant strides toward its core mission of revolutionizing pathology image analysis with AI and delivering improved care for every patient. I am immensely proud of our collective accomplishments and energized for the progress we will continue to make.
The digital transformation of pathology is accelerating, and Aiforia is at the forefront of this evolution. Our strong team and cutting-edge offerings position us for continued success in this dynamic market. This past year, we have seen several European healthcare providers successfully integrate Aiforia's AI solutions into their clinical diagnostics workflows, confirming the value of our technology.
Aiforia's 2025 key achievements include:
-
We successfully acquired new customers and completed essential clinical customer deployments in multiple countries, including France, Spain, Finland, Denmark, the UK, and Turkey.
-
We strengthened our local presence in France by establishing a subsidiary in the country. Building on the successful 2024 collaboration with AP-HP hospital group in Paris, our foothold in the country grew significantly, with new partners like Nantes University Hospital and Institut Curie choosing Aiforia as a partner for AI-assisted pathology diagnostics.
-
Our sales reach was expanded through the establishment of multiple key sales and marketing partnerships, notably a collaboration with Siemens Healthineers.
-
In February, we reached a monumental regulatory milestone: successfully achieving IVDR certification for the selection of AI solutions focused on breast and prostate cancer diagnostics.
-
Throughout the year, we launched several additional CE-IVD marked AI solutions, including a market-leading Breast Cancer Grading AI solution with five AI models and a solution for Lymph Node Metastases for three primary cancers. Today, Aiforia now holds the broadest portfolio of CE-IVD marked solutions available in the pathology market.
-
We expanded our core AI technology platform with the Vision Transformer architecture, introducing the Foundation Engine and leveraging it in product development. In December 2025, we released Aiforia 7.0, bringing the Foundation Engine to users of our unique Aiforia® Create tool.
- Building on the momentum of our collaboration with Orion, announced in March, we enhanced our preclinical workflow solution. This led to the December launch of a new version of the Aiforia® Studies module, which includes an advanced data capture module specifically designed for effective recording of preclinical study findings.
As 2025 comes to a close, I want to express my deepest gratitude to everyone who contributed to Aiforia's success this year. Your hard work, commitment, and support have been the driving force behind our progress. We are fully committed to seizing the opportunities within the rapidly evolving AI-driven digital pathology landscape and look forward to continuing our mission to advance patient care through AI innovation in the coming year.
Wishing you a season filled with warmth, joy, and peace.
Jukka Tapaninen
CEO
Aiforia Technologies Plc